Quote:
Originally Posted by Rrrrrachel 
I know we're mostly done here, but I came across some of these today and the threads not locked yet, soooo . . . .
Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations.
http://www.ncbi.nlm.nih.gov/pubmed/16818529
Examined birth cohorts in Canada from 1987 to 1998 and looked for trends in pervasive developmental disorders and a relationship with exposure to thimerosal and mmr. Thimerosal exposure ranged from none to medium (around 100 mcg) to high (around 200 mcg). The prevalence of pdd was significantly higher in the thimerosal free group than the thimerosal exposed group. Rates of pdd were also found to significantly increase when rates of mmr decreased.
Association between thimerosal-containing vaccine and autism.
http://www.ncbi.nlm.nih.gov/pubmed/14519711
Compared birth cohorts born in Denmark between 1990 and 1996. Compared children given a thimerosal containing vaccine to children vaccinated with a thimerosal free version of the same vaccine. Risk of autism did not vary significantly between the groups.

I know we're mostly done here, but I came across some of these today and the threads not locked yet, soooo . . . .
Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations.
http://www.ncbi.nlm.nih.gov/pubmed/16818529
Examined birth cohorts in Canada from 1987 to 1998 and looked for trends in pervasive developmental disorders and a relationship with exposure to thimerosal and mmr. Thimerosal exposure ranged from none to medium (around 100 mcg) to high (around 200 mcg). The prevalence of pdd was significantly higher in the thimerosal free group than the thimerosal exposed group. Rates of pdd were also found to significantly increase when rates of mmr decreased.
Association between thimerosal-containing vaccine and autism.
http://www.ncbi.nlm.nih.gov/pubmed/14519711
Compared birth cohorts born in Denmark between 1990 and 1996. Compared children given a thimerosal containing vaccine to children vaccinated with a thimerosal free version of the same vaccine. Risk of autism did not vary significantly between the groups.
These studies are shredded in www14studies.org.
The Canadian study analyzed here: http://www.14studies.org/MMR_3_details.html
"Used a statistical trick by using MMR uptake data from one city (Quebec City) and comparing it to autism rates in a different city (Montreal)."
The Canadian study asks and answers these questions:
"Q: Are MMR uptake and PDD rates related in Montreal? [Remember, they're using MMR uptake data from Quebec, not Montreal.]
A: No
Did the study look at unvaccinated children?
A: No"
Is there any potential Conflict of Interest in the Canadian study?
Um, yes.
"In the United Kingdom, Dr Fombonne has provided advice on the epidemiology and clinical aspects of autism to scientists advising parents, to vaccine manufacturers, and to several government committees between 1998 and 2001. Since June 2004, Dr Fombonne has been an expert witness for vaccine manufacturers in US thimerosal litigation."
According to another researcher, Ed Yazbak, Fombonne et al (authors of the Canadian study) "ignored the fact that autism rates increased following a doubling of the MMR exposure after 1996 when a second MMR shot was added to the immunization schedule and chose to emphasize that a rise in PDD rates coincided with a decline in MMR coverage rates."





Follow Mothering